Amyotrophic lateral Sclerosis Mimic Syndromes, A Population-Based Study
Arch Neurol 57:109-113, Traynor,B.J.,et al, 2000
Total Brain N-Acetylaspartate, A New Measure of Disease Load in MS
Neurol 54:15-19, Gonen,O.,et al, 2000
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Pathologic Damage in MS Assessed by Diffusion-Weighted and Magnetization Transfer MRI
Neurol 54:1139-1144, Cercignani,M.,et al, 2000
Progressive Cerebral Atrophy in MS
Neurol 54:807-812,782, Fox,N.C.,et al, 2000
Glossopharyngeal Neuralgia and MS
Neurol 54:1368-1370, Minagar,S.&Sheremata,W.A., 2000
Primary Neurosarcoidosis:A Diagnostic and Therapeutic Challenge
The Neurologist 6:126-133, Nikhar,N.K.,et al, 2000
Outcome of Surgery for Thoracic Outlet Syndrome in Washington State Workers' Compensation
Neurol 54:1252-1257, Franklin,G.M.,et al, 2000
Multiple Sclerosis and Antecedent Infections
Neurol 54:2307-2310, Marrie,R.A.,et al, 2000
Diagnostic Criteria for Primary Progressive Multiple Sclerosis: A Position Paper
Ann Neurol 47:831-835, Thompson,A.J.,et al, 2000
Heterogeneity ofMultiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination
Ann Neurol 47:707-717, Lucchinetti,C.,et al, 2000
Open-Ring Imaging Sign
Neurol 54:1427-1433, Masdeu,J.C.,et al, 2000
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Neurologic and Developmental Disability After Extremely Preterm Birth
NEJM 343:378-384,429, Wood,N.S. et al, 2000
Functional Outcomes After Gamma Knife Thalamotomy for Essential Tremor and MS-Related Tremor
Neurol 55:443-446, Niranjan,A. et al, 2000
Cerebrospinal Fluid Oligoclonal IgG Bands in Patients With Spinal Arteriovenous Malformation and Structural Central Nervous System Lesions
Arch Neurol 57:553-557, Cohen,O.,et al, 2000
Poliomyelitic-Like Illness in Central European Encephalitis
Neurol 55:299-302, Schellinger,P.D. et al, 2000
Optic Neuritis in Multiple Sclerosis: An Update
The Neurologist 6:205-213, Chan,J.W., 2000
Disability in Young People and Adults One Year after Head Injury: Prospective Cohort Study
BMJ 320:1631-1635, Thornhill,S. et al, 2000
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Psychological Stress and the Subsequent Appearance of New Brain MRI Lesions in MS
Neurol 55:55-61, Mohr,D.C. et al, 2000
Acute Aphasia in Multiple Sclerosis
Arch Neurol 57:1207-1209, Devere,T.R. et al, 2000
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Cerebral Infarctin in the Term Newborn: Clinical Presentation and Long-Term Outcome
J Pediatr 137:351-355, Sreenan,C. et al, 2000
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis
NEJM 343:898-904, Jacobs,L.D. et al, 2000
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
A 44-Year-Old Woman with Difficulty Walking
JAMA 284:2632-2639, Iezzoni,L.I., 2000
The Clinical Spectrum of Anti-GAD Antibody-Positive Patients with Stiff-Person Syndrome
Neurol 55:1531-1535, Dalakas,M.C.,et al, 2000
Conjugal Multiple Sclerosis: Population-Based Prevalence and Recurrence Risks in Offspring
Ann Neurol 48:927-931, Evers,G.C.,et al, 2000
Relative Contributions of Brain and Cervical Cord Pathology to Multiple Sclerosis Disability: a Study with Magnetisation Transfer Ratio Histogram Analysis
JNNP 69:723-727, Rovaris,M.,et al, 2000
Topiramate Relieves Refractory Trigeminal Neuralgia in MS Patients
Neurol 55:1587-1588, Zvartau-Hind,M.,et al, 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Utilization of Unconventional Treatments by Persons with MS:Is It Alternative or Complementary?
Neurol 52:626-629, Schwartz,C.E.,et al, 1999
Multiple Sclerosis Associated with Uveitis in Two Large Clinic-Based Series
Neurol 52:179-181, Biousse,V.,et al, 1999
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Magnetization Transfer Imaging of Patients with Definite MS and Negative Conventional MRI
Neurol 52:845-848, Filippi,M.,et al, 1999
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Quantitative MRI in CADASIL, Correlation with Disability and Cognitive Performance
Neurol 52:1361-1367, Dichgans,M.,et al, 1999
Burden of Migraine in the United States, Disability and Economic Costs
Arch Int Med 159:813-818, Hu,X.H.,et al, 1999
Changes in Resource Use and Outcomes for Patients with Migraine Treated with Sumatriptan, A Managed Care Perspective
Arch Int Med 159:857-863, Lofland,J.H.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999